Differential impact of GVHD prophylaxis on CMV infection and survival outcomes after cord blood transplantation in the era of letermovir. (PubMed, Transplant Cell Ther) - Sep 7, 2026 - "This study evaluated the impact of GVHD prophylaxis with methotrexate (MTX) versus mycophenolate mofetil (MMF) after CBT on CMV infection and survival outcomes, considering the use of letermovir (LTV) prophylaxis. Importantly, LTV mitigated the disadvantage of MTX with respect to csCMVi, and patients receiving MTX with LTV exhibited a lower NRM than those receiving MMF with LTV (11.5% vs. 17.8%, P = 0.003), a finding that remained significant in multivariable analysis. This study highlights the potential for further optimization of GVHD and infectious prophylaxis strategies in CBT, thereby reducing NRM while maintaining a potent GVT effect."
Journal • Acute Graft versus Host Disease • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Oncology • Transplantation
|
|
Atsushi Wake; Hideki Nakasone; Hiroyuki Muranushi; Junya Kanda; Keisuke Kataoka; Kimikazu Yakushijin; Koji Kato; Makoto Onizuka; Mamiko Sakata-Yanagimoto; Marie Ohbiki; Masashi Sawa; Masatsugu Tanaka; Naoyuki Uchida; Noriko Doki; Shingo Yano; Shunto Kawamura; Takeshi Maeda; Tetsuya Nishida; Tomomi Toubai; Toshihiro Matsui; Toshiro Kawakita; Yoshiko Atsuta; Yoshinobu Kanda; Yu Akahoshi; Yuta Hasegawa
|